Psych’s third annual report on psychedelic medicine revealed some interesting findings.
According to a survey of 440 healthcare professionals working in various fields, two thirds said they were excited about psychedelics as medicines. Of those who’ve personally tried the drugs for therapeutic or spiritual purposes, 83% were in favour of psychedelic medicine.
Consumers also showed a positive view of psychedelics, with about two thirds supporting medical legalization and 38% noting that someone they know would benefit from psychedelic therapy. When asked which psychedelic they would want to try in therapy, psilocybin and salvia were the most popular choices.
The report also showed that psychedelic therapy could save employers US$64 billion in Europe and US$270 billion in America due to fewer sick days and increased productivity.